CENTESSA PHARMACEUTICALS PLC
CNTALoading price...
Overview
Previous Close27.58
Open40.03
Ask39.78
Bid39.61
Day's Range39.57 - 40.25
52 Week Range9.60 - 40.25
PE Ratio(TTM)--
Market Cap5.8B
Volume47.69M
Avg. Volume1.43M
12 Months Earnings-223.85M
12 Months Revenue15.00M
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Operating Revenue | 15.00M | 0.00 | 6.85M | 0.00 | 0.00 |
| Operating Expenses | 210.74M | 201.06M | 178.14M | 210.28M | 10.44M |
| Profit after Tax (Net Income) | -223.85M | -235.76M | -151.09M | -216.21M | -10.66M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Altrincham, United Kingdom
Website: https://centessa.com
CFO & Principal Financial Officer: Mr. John J. Crowley CPA
Employees: 114
About Company:
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.